Can You Test for a Schizophrenia Gene?

No single “schizophrenia gene” exists, so there is no test that can look at one spot in your DNA and tell you whether you will develop the condition. Schizophrenia’s genetic architecture involves thousands of common variants, each nudging risk by a tiny amount, alongside a handful of rare mutations that carry more weight individually but are found in only a small fraction of people. Genetic testing related to schizophrenia does exist in several forms, but none of them work the way a test for, say, sickle cell disease works, and understanding what they can and cannot tell you matters if you or a family member is considering one.

Why There Is No Single Gene to Test For

Schizophrenia is highly heritable. Twin and family studies put heritability somewhere between 60 and 80 percent, meaning that the majority of the variation in who develops it versus who does not traces back to genetic differences rather than purely environmental ones.¹ But that high heritability is spread across an enormous number of genetic variants. A landmark genome-wide study provided molecular evidence that a “substantial polygenic component” underlies schizophrenia risk, involving thousands of common gene variants, each with a very small effect.² Later work estimated that roughly 8,300 independent genetic markers contribute to risk, collectively accounting for about a third of the overall genetic liability.¹

Think of it less like a light switch and more like a dimmer controlled by thousands of tiny hands, each turning it up or down by a barely perceptible amount. No single hand matters much on its own. This is the fundamental reason a straightforward “yes or no” genetic test for schizophrenia does not exist and is unlikely to exist anytime soon. The genetics are real and powerful in aggregate, but they are distributed so widely across the genome that testing any one spot tells you almost nothing.

Rare Variants That Carry Real Risk

While most of schizophrenia’s genetic risk comes from common variants of tiny effect, researchers have also identified rare mutations that carry considerably more weight. These fall into two broad categories: copy number variants, which are deletions or duplications of stretches of DNA, and ultra-rare coding variants, which are changes within specific genes that alter the protein those genes produce.

Among copy number variants, one of the most studied is a deletion on chromosome 22, known as 22q11.2 deletion syndrome. People born with this deletion have a substantially elevated risk of developing schizophrenia and several other neurodevelopmental conditions. A review of the evidence notes that rare copy number variants like this one show “unprecedented levels of statistical association” with schizophrenia, autism, intellectual disability, and ADHD.³ Clinicians can test for 22q11.2 deletion, and it is one of the few genetic findings in psychiatry that has clear diagnostic relevance, though the deletion is found in only a small minority of people with schizophrenia.

On the rare coding variant side, a large exome study comparing over 24,000 schizophrenia cases to nearly 100,000 controls identified ultra-rare coding variants in ten genes that confer substantial risk, with odds ratios ranging from about 3 to 50.⁴ An odds ratio of 50 is enormous in genetics. But “ultra-rare” is the key qualifier: these mutations are found in so few people that their discovery, while scientifically important, does not translate into a useful screening tool for the general population. They matter most for understanding what goes wrong biologically and for identifying the small subset of patients whose illness may be driven by a specific genetic change.

Research on especially severe, treatment-resistant schizophrenia reinforces this picture. In one study, about 48 percent of people with the most severe, treatment-resistant form of the illness carried at least one rare, damaging mutation in genes that are normally tightly conserved, compared to about 30 percent of people with typical schizophrenia and 25 percent of healthy controls.⁵ When the analysis was restricted to genes already known to be associated with schizophrenia, about 9 percent of people with severe treatment-resistant illness carried a damaging variant, compared to around 2 percent of typical cases and under 2 percent of controls.⁵ These numbers suggest that rare variants may play a larger role in the most disabling forms of the disorder, which has implications for who might benefit most from genetic testing.

Polygenic Risk Scores and Why They Are Not Ready for the Clinic

If thousands of common variants each contribute a sliver of risk, the natural idea is to add them all up into a single number. That is exactly what a polygenic risk score does. Researchers take a person’s DNA, check which common risk variants they carry, weight each one by its estimated effect size, and sum the whole thing into a score. In research settings, polygenic risk scores for schizophrenia can distinguish groups of cases from groups of controls with decent statistical power.

The problem is that “decent for research” is nowhere near “useful for an individual.” A 2025 study evaluating the clinical utility of polygenic risk scores for major psychiatric disorders found that the sensitivity for schizophrenia scores was good, in the range of 90 to 93 percent. But specificity was poor, hovering around 50 to 56 percent across all the disorders tested.⁶ That means the scores are good at catching people who do have the disorder but terrible at correctly ruling out people who do not. Essentially, too many healthy people would be flagged as high risk.

There is an even more fundamental stability problem. The same study found that fewer than half of people identified as being in the top 5 percent of schizophrenia risk by one version of the polygenic risk score were also identified as high risk by a different version of the score built from different reference data.⁶ If your “high risk” label depends on which particular algorithm was used, and flipping to a slightly different one moves you out of the high-risk category, the score is not stable enough to guide clinical decisions. The researchers concluded that these limitations highlight a current lack of clinical utility for polygenic risk scores in psychiatry.

Genetic Tests That Actually Exist in Practice

Given all the caveats above, what can a clinician or patient actually order today? There are a few real-world options, each with a different purpose and a different level of usefulness.

Chromosomal microarray analysis is the closest thing to a standard genetic test for schizophrenia in clinical settings. It scans the genome for copy number variants, the kinds of deletions and duplications discussed earlier. One research group that performed microarray analysis on 60 schizophrenia patients detected pathogenic or likely pathogenic copy number variants in about 7 percent of them and recommended the test as a first-tier genetic tool for schizophrenia spectrum disorders.⁷ A larger community study found a similar overall detection rate of about 7 percent for pathogenic copy number variants, but with a dramatic split by cognitive ability: the yield was about 3 percent in people with average IQ but rose to around 24 percent in people with co-occurring intellectual disability.⁸ If you have schizophrenia and co-occurring intellectual disability or certain developmental features, a chromosomal microarray has a reasonable chance of finding something actionable. If you have schizophrenia with otherwise typical cognitive functioning, the odds are much lower.

Direct-to-consumer genetic testing companies offer genotyping that includes some psychiatric-related variants, but these products are not designed or validated as diagnostic tools for schizophrenia. They might report a handful of individual risk markers, but without the full polygenic context and without clinical interpretation, the results are more likely to confuse than to clarify. The controversy over marketing psychiatric genetic tests to consumers has been simmering for years, with researchers divided on whether partial genetic information does more harm than good when people lack the context to interpret it.

What Biology the Genetics Point To

Even though genetic testing cannot yet predict schizophrenia reliably, the genetic findings have been enormously valuable for understanding what goes wrong in the brain. Two biological themes keep emerging from the data.

The first is synaptic pruning. During normal brain development, especially in adolescence and early adulthood, the brain eliminates excess synaptic connections in a process that refines neural circuits. Research has tied a gene called C4, part of the immune system’s complement pathway, to this process. The C4 protein was found at synapses in the human brain, and increased C4 activity was associated with schizophrenia risk. In mice lacking functional C4, synaptic pruning was reduced, paralleling what had been seen in mice lacking other complement proteins.⁹ Follow-up work has shown that C4 overexpression can trigger pathological synapse loss through a mechanism involving disrupted trafficking of a receptor critical for synaptic communication.¹⁰ The idea, in plain terms, is that some people’s brains prune too aggressively during development, stripping away connections that should have been kept.

The second theme involves signaling through a specific brain receptor, the NMDA receptor, which plays a central role in how neurons communicate and in processes like learning and memory. Two decades of converging evidence from genetics, drug studies, and brain chemistry have pointed to reduced function of this receptor as a key contributor to schizophrenia.¹¹ Gene association studies have found that several of the genes whose variants raise schizophrenia risk are directly involved in regulating how this receptor works.¹² These biological insights do not help with prediction today, but they are shaping the development of new treatments that target specific pathways rather than broadly flooding the brain with dopamine-blocking drugs.

How Environment Shapes What Genes Do

Even among people carrying a heavy genetic load for schizophrenia, many never develop the disorder. Environment matters, and not just as an independent risk factor. Genes and environment interact, sometimes through a process called epigenetics, where environmental exposures change how genes are read without altering the DNA sequence itself. Chemical tags on DNA and surrounding proteins can be modified by stress, nutrition, infection, and other experiences, effectively turning genes up or down.¹³

Animal research has demonstrated this concretely. Mice exposed to prenatal stress showed behavioral changes resembling schizophrenia symptoms, along with epigenetic modifications at specific genes in the brain, including changes in DNA methylation patterns at a gene involved in brain growth and plasticity.¹⁴ In humans, the picture is messier but consistent with the same general principle: early adversity, infections during pregnancy, urban upbringing, social isolation, and substance use all appear to raise risk, and genetic vulnerability may amplify the effect of these exposures.

Cannabis is one of the more closely studied environmental factors. Research has found that people with higher polygenic risk scores for schizophrenia were more likely to use cannabis, suggesting that genetic predisposition and cannabis use are not fully independent risk factors but are partly entangled.¹⁵ This does not mean cannabis is harmless for people without genetic risk, but it does complicate the interpretation of genetic testing: even if you knew your polygenic score, predicting your actual risk would require accounting for a web of environmental exposures that no genetic test can capture.

The Ancestry Problem

Most of the large genetic studies that have mapped schizophrenia risk loci were conducted in people of European ancestry. This is a serious limitation. Polygenic risk scores derived from these studies work best in European-ancestry populations and lose predictive power in people of other backgrounds. One long-term study tracking psychotic disorders over 20 years noted explicitly that the primarily European ancestry of the data underpinning the scores “reduces the predictive power of polygenic risk scores in other ancestry groups.”¹⁶

This means that any genetic test based on current data is inherently less informative for people of African, East Asian, South Asian, Latin American, or Indigenous descent. Efforts are underway to diversify the reference populations used in genetic studies, but progress has been slow. If you are not of European descent and someone offers you a polygenic risk score for schizophrenia, the result should be treated with extra skepticism, because the tool was not calibrated for your genetic background.

Genetic Overlap With Other Conditions

Another reason a schizophrenia-specific genetic test is so difficult to build is that many of the genetic variants implicated in schizophrenia also raise risk for bipolar disorder, autism, ADHD, and other conditions. The diagnostic boundaries between these disorders are based on symptoms and clinical judgment, not on biology, and the genetics do not respect those boundaries. Studies using genome-wide data have shown overlap between the genetic loci and even the specific gene variants that predispose to schizophrenia, bipolar disorder, and autism.¹⁷

This genetic overlap means that even a perfect polygenic risk score for “schizophrenia” would partly be a risk score for psychosis broadly, or for neurodevelopmental vulnerability in general. A high score might mean you are at elevated risk for schizophrenia specifically, or it might mean you are at elevated risk for bipolar disorder with psychotic features, or for a schizoaffective presentation, or for something that clinicians have not yet cleanly categorized. The genes do not come with diagnostic labels attached.

Pharmacogenomic Testing for Treatment

While genetic testing cannot reliably predict who will develop schizophrenia, there is one area where genetic information is already clinically useful for people who have the diagnosis: choosing medications. Pharmacogenomic tests examine genes that influence how your body metabolizes drugs. Two people taking the same antipsychotic at the same dose can have vastly different blood levels of the medication, and much of that variation traces to genetic differences in liver enzymes that break the drug down.

Pharmacogenomic testing can identify whether you are a rapid metabolizer who clears a drug so quickly it never reaches effective levels, or an ultra-slow metabolizer at risk for side effects because the drug accumulates. Research has characterized these relationships for several antipsychotic medications, and clinical tests for the relevant genetic markers are available.¹⁸ A systematic review examining whether pharmacogenetic testing influences real-world outcomes in people on antipsychotic treatment found that the approach holds promise for preventing adverse drug reactions and improving how well treatment works, though the evidence base is still developing.¹⁹

If you are already being treated for schizophrenia and struggling with side effects or lack of response, asking your psychiatrist about pharmacogenomic testing is a more immediately practical use of genetics than any risk prediction tool currently available.

Genetic Counseling and What It Can Offer

For families affected by schizophrenia, the question of genetic testing often arises not from idle curiosity but from real concern: will my children be at risk? Will my sibling develop it too? Genetic counseling for psychiatric conditions is a growing field that aims to help people understand what current science can and cannot tell them. A review of psychiatric genetic counseling for schizophrenia emphasized that counseling can help patients and families make meaningful decisions about genetic testing, set realistic expectations, and reduce the stigma and discrimination that can come from misunderstanding genetic results.²⁰

Research on outcomes of genetic counseling for psychiatric conditions has shown that it can improve empowerment, helping people feel more in control of their situation and less trapped by a sense of genetic inevitability.²¹ A good genetic counselor will walk through the family history, explain the difference between heritability at a population level and individual risk, and help frame the current limitations of testing honestly. For many families, the conversation itself, quite apart from any test result, turns out to be what they needed most.

Legal and Forensic Questions Around Genetic Evidence

As genetic testing technology advances, questions have begun to surface about whether genetic evidence of schizophrenia risk or predisposition should play a role in legal proceedings. In Indonesia, for example, researchers examined the criminal justice system’s framework for handling DNA screening evidence related to schizophrenia and found significant gaps. The existing criminal procedure code does not explicitly recognize DNA-based evidence for mental disorders, creating legal uncertainty and raising concerns about potential human rights violations for defendants with psychiatric conditions.²²

This is an early-stage debate, but it touches on issues that will only grow more pressing. If polygenic risk scores improve, courts and insurance companies will face questions about whether genetic predisposition should influence sentencing, liability, or coverage. The scientific community has generally urged extreme caution here: current genetic tools cannot diagnose schizophrenia, cannot predict with any confidence whether a given individual will develop it, and absolutely cannot explain whether a person’s behavior at a specific moment was influenced by their genetic makeup. Using genetic data in legal or forensic settings before the science supports it risks encoding biological determinism into law, a concern that ethicists and geneticists have been raising for years.

Why Schizophrenia Risk Genes Persist in the Population

Given that schizophrenia is associated with reduced reproduction and higher mortality, you might wonder why natural selection has not eliminated the risk variants. This is sometimes called the evolutionary paradox of schizophrenia. The disorder occurs at a prevalence of roughly 1 percent worldwide, and its heritability hovers around 70 percent, yet the genetic variants that contribute to risk remain common in human populations.²³

Several explanations have been proposed. One is that many schizophrenia risk variants also influence traits that are beneficial in other contexts, such as creativity, cognitive flexibility, or immune function, so they are maintained by a balance between costs in some individuals and advantages in others. Another is that the sheer number of contributing variants, each with a tiny effect, means that natural selection acts weakly on any single one. A variant that raises schizophrenia risk by 0.01 percent while doing something mildly useful elsewhere in the body is essentially invisible to evolutionary pressure. The practical upshot for genetic testing is that these risk variants are woven deeply into ordinary human genetic variation. You cannot draw a clean line between “schizophrenia genes” and “normal genes,” because they are, in most cases, the same genes doing slightly different things in different people.